Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $573.4 million
Deal Type : Collaboration
Boehringer and Tessellate Partner for Precision Cancer Therapies
Details : The collaboration of Tessellate Bio with Boehringer will focus on the development of first-in-class, oral precision treatments for people living with cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 23, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $573.4 million
Deal Type : Collaboration
Tessellate BIO, Omico, CMRI Partner On Synthetic Lethal Cancer Therapies
Details : The collaboration will advance the understanding of the prevalence of ALT across tumor types and the genetic factors involved, and accelerate the precision medicine tools and new cancer therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : BioGeneration Ventures
Deal Size : $8.4 million
Deal Type : Financing
Tessellate BIO Emerges from Stealth
Details : The financing will be used to focun on company's lead program that targets the DNA damage response (DDR) and in particular cancers that depend on Alternative Lengthening of Telomeres (ALT).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 17, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : BioGeneration Ventures
Deal Size : $8.4 million
Deal Type : Financing
Reset All
